Ventyx Biosciences sets IPO terms, to be valued at up to $804 million
Ventyx Biosciences Inc.
VTYX,
has set terms for its initial public offering, in which the California-based biopharmaceutical company focused on inflammatory disease treatments looks to raise up to $132.8 million. The company is offering 7.81 million shares…
